| ☒ |
ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|
| ☐ |
TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934
|

|
Delaware
|
77-0390628
|
|
|
(State or other jurisdiction of incorporation or organization)
|
(I.R.S. Employer Identification No.)
|
|
308 Dorla Court,
Suite 206
Zephyr Cove, Nevada |
89448
|
|
|
(Address of principal executive offices)
|
(Zip Code)
|
|
Title of each class
|
Trading Symbol(s)
|
Name of each exchange on which registered
|
||
|
Common Stock, par value $0.0001 per share
|
VHC
|
NYSE
|
|
Large accelerated filer ☐
|
Accelerated filer ☐
|
Non-accelerated filer ☒
|
|
Emerging growth company ☐
|
Smaller reporting company ☒
|
|
Page
|
||
|
PART I
|
||
|
Item 1.
|
2
|
|
|
Item 1A.
|
8 | |
|
Item 1B.
|
19 | |
|
Item 1C.
|
20 | |
|
Item 2.
|
21 | |
|
Item 3.
|
22 | |
|
Item 4.
|
22 | |
|
PART II
|
||
|
Item 5.
|
22 | |
|
Item 6.
|
22 | |
|
Item 7.
|
23 | |
|
Item 7A.
|
27
|
|
|
Item 8.
|
27 | |
|
Item 9.
|
47 | |
|
Item 9A.
|
47 | |
|
Item 9B.
|
47 | |
|
Item 9C.
|
48 | |
|
PART III
|
||
|
Item 10.
|
48 | |
|
Item 11.
|
48 | |
|
Item 12.
|
48 | |
|
Item 13.
|
49 | |
|
Item 14.
|
49 | |
|
PART IV
|
||
|
Item 15.
|
49 |
| Item 1. |
Business
|
| • |
Direct sales efforts with larger users, particularly those engaged in defense and other governmental or national initiatives.
|
|
|
• |
Actively recruit partners in various vertical markets, including critical infrastructure, intelligence, defense, healthcare, finance, legal, government to help us expand our enterprise customer base.
|
|
|
• |
Promote our next-generation VirnetX One™ platform as a solution for delivering ZTNA, and securing enterprise applications, services, and infrastructure.
|
|
|
• |
Combine with VirnetX One™ platform with technologies from the companies we have invested in, namely OmniTeq and OPMedia, to enhance their offerings and provide supplemental sales channels for VirnetX One™
|
|
|
• |
Continue to grow our technology licensing program to commercialize our intellectual property.
|
|
|
• |
Grow registration of VirnetX Secure Domain Names as the network segmentation component of our ZTNA solution. Establish VirnetX as the exclusive, universal registry of secure domain names and enable our
customers to act as registrars for their users and broker secure communication between devices.
|
|
|
• |
Promote War RoomTM video conferencing product in the general market for sale to end-user enterprises, directly and with
partners, with targeted promotions and other marketing programs to assist remote workers and offer an industry leading secure meeting solution.
|
| • | Promote VirnetX MatrixTM applications, services, and infrastructure. |
| • | Integrate advanced AI/ML algorithms and models into the VirnetX OneTM platform for enhancements. |
| • | Explore quantum cryptographic solutions and blockchain applications to improve zero-trust security, to future-proof our software. |
|
|
• |
Unique patented technology. We are focused on developing innovative technology for securing real-time communications over the Internet and establishing the exclusive
secure domain name registry in the United States and other key markets around the world. Our unique solutions combine industry standard encryption methods and communication protocols with our patented techniques for automated DNS lookup
mechanisms. Our technology and patented approach enable users to create a secure communication link by generating secure domain names. We currently own U.S. and foreign patents/validations/pending applications. Our portfolio includes
patents and pending patent applications in the United States and other key markets that support our secure domain name registry service for the Internet.
|
|
|
• |
Scalable licensing business model. We are actively engaged in pursuing additional licensing agreements with industry participants OEMs, service providers and system
integrators within the IP-telephony, mobility, mobile-to-mobile communications, fixed-mobile convergence, and unified communications end-markets.
|
|
|
• |
Highly experienced research and development team. Our research and development team is comprised of nationally recognized network security and encryption technology
scientists and experts that have worked together as a team for over ten years. During their careers, this team has developed several cutting-edge technologies for U.S. national defense, intelligence, and civilian agencies, many of which
remain critical to our national security today. Prior to joining VirnetX, our team worked for Leidos, during which time they invented the core technology that is the foundation of our current technology and software. Based on the
collective knowledge and experience of our development team, we believe that we have one of the most experienced and sophisticated groups of security experts researching vulnerability and threats to real-time communication over the
Internet and developing solutions to mitigate these problems.
|
|
|
• |
We established an advisory board comprised of four retired senior U.S. Air Force leaders to assist and advise on business development and
operational direction of VirnetX’s Zero Trust Network Access security technology as a necessary layer of security for defense communications and data management to Department of Defense government officials and commercial contractors.
|
|
|
• |
We participated in the U.S. Navy Expeditionary Combat Command (NECC) sponsored technology demonstrations during the Rim of the Pacific (RIMPAC)
2024, a large-scale international maritime exercise at Ford Island, Oahu, Hawaii, and successfully demonstrated our VirnetX One Matrix and VirnetX’s War Room secure video conferencing from ship to shore environments. We believe our
technology and solutions can fill defense needs for security, stealth, and flexibility in myriad day-to-day static situations to the most challenging operations in conflict or humanitarian assistance.
|
|
|
• |
We participated in a Cooperative Research and Development Agreement (CRADA) with the Air Force (AF) Research Laboratory Intelligence Systems
Directorate (AFRL/RI) to facilitate collaboration on cybersecurity and Zero Trust technologies to support integrated surveillance and reconnaissance operations as well as AF and joint targeting processes. The work conducted under this
CRADA is expected to provide the avenue to secure and obfuscate AF targeting, processing, dissemination, and intelligence technology, enabling AF to take advantage of the latest research and developments in commercially available
cybersecurity technology and reduce its IT attack surface in a joint, all-domain environment.
|
|
|
• |
We hired Dr. John Anthony Jamison as new VirnetX Chief Technical Officer (CTO). Dr. Jamison brings a wealth of technology experience in the
intelligence community and will be instrumental as expand our participation in national defense projects and initiatives.
|
|
|
• |
We successfully conducted a rigorous functional and penetration testing of our VirnetX One Matrix solution by Pacific Northwest National
Laboratory (PNNL) with support from Johns Hopkins University Applied Physics Laboratory (JHU-APL) at the request of The United States Space Force (USSF).
|
|
|
• |
Patent Assignment. Leidos, unconditionally and irrevocably conveyed, transferred, assigned, and quitclaimed all its right, title, and interest in and to the patents and
patent applications, as specifically set forth in the assignment document recorded with the U.S. Patent Office, including, without limitation, the right to sue for past infringement.
|
|
|
• |
License to Leidos, Outside the Field of Use. Effective March 12, 2008, we granted to Leidos, a non-exclusive, royalty free, fully paid, perpetual, worldwide,
irrevocable, sub licensable and transferable right and license permitting Leidos, and its assignees to make, have made, import, use, offer for sale, and sell products and services covered by, and to make improvements to, the patents and
patent applications we acquired from Leidos, solely outside our field of use.
|
|
|
• |
Compensation Obligations. As consideration for the assignment of the patents and for the rights we obtained from Leidos, as amended, we are required to make payments to
Leidos, based on cash or certain other values generated from those patents. The amount of such payments depends upon the type of value generated, and certain categories are subject to maximums and other limitations. In 2010, we met our
maximum royalty payment requirement; however, Leidos is also entitled under certain circumstances to receive a portion of the proceeds paid to us for certain acquisitions of VirnetX and the settlement of certain patent infringement
claims of ours.
|
| • |
Time and resources required to accelerate transition to new product development and sales strategies targeting large enterprises, government customers, service provider partnerships and grant funding;
|
| • |
Our success depends in part on establishing and maintaining relationships with third parties to integrate our family of cybersecurity products and services into their operations and develop solutions key
to the defense market, critical infrastructure and threat intelligence service;
|
| • |
Customer adoption of our VirnetX One™ platform and software products and services;
|
| • |
The number of product license sales of VirnetX War Room™, VirnetX Matrix™ and associated services;
|
| • |
Adoption of VirnetX OneTM platform by third party application providers of secure communications;
|
| • |
Intensely competitive market with established companies that have larger customer bases, and greater resources than we do;
|
| • |
Prolonged economic uncertainties or downturns, globally or in certain regions or industries, could materially adversely affect our business; and
|
| • |
Government export and import control regulations on selling products with encryption technology in certain international markets.
|
| • |
The need to educate potential customers about our product and service capabilities;
|
| • |
Our customers’ budgetary constraints and timing of their budget cycles;
|
| • |
Delays caused by time-consuming internal review processes customary with potential customers including large governments agencies and institutions in the space and defense industries; and
|
| • |
Long sales cycles may increase the risk that our financial resources are exhausted before we are able to generate significant revenue.
|
| • |
Implement an effective marketing strategy to promote awareness of our products;
|
| • |
Attract and retain customers for our products;
|
| • |
Generate revenues or profit from product sales;
|
| • |
Provide appropriate levels of customer training and technical support for our products;
|
| • |
Rapidly anticipate and adapt to changes in the market and evolving customer requirements;
|
| • |
Protect our products from any system failures or other breaches.
|
| • |
Power loss, transmission cable cuts and other telecommunications failures;
|
| • |
Damage or interruption caused by fire, earthquake, and other natural disasters;
|
| • |
Computer viruses, electronic break-ins, sabotage, vandalism or software defects; and
|
| • |
Physical or electronic break-ins, sabotage, intentional acts of vandalism, terrorist attacks and other events beyond our control.
|
| • |
A staggered Board of Directors: Only one or two of five directors will be up for election at any given annual meeting, delaying the ability of stockholders to affect a change in control of us because it
would take two annual meetings to effectively replace a majority of the Board of Directors.
|
| • |
Blank check preferred stock: Our Board of Directors has the authority to establish the rights, preferences, and privileges of our 10,000,000 authorized, but unissued, shares of preferred stock. Therefore,
this stock may be issued at the discretion of our Board of Directors with preferences over your shares of our common stock in a manner that is materially dilutive to you. In addition, blank check preferred stock can be used to create a
“poison pill” which is designed to deter a hostile bidder from buying a controlling interest in our stock without the approval of our Board of Directors. We have not adopted such a “poison pill;” but our Board of Directors can do so in
the future, very rapidly and without stockholder approval.
|
| • |
Advance notice requirements for director nominations and for business to be brought before stockholder meetings: Stockholders wishing to submit director nominations or raise matters to a vote of the
stockholders must provide notice to us within very specific date windows and in very specific form to have the matter voted on at a stockholder meeting. This gives our Board of Directors and management more time to react to stockholder
proposals generally and could also permit us to disregard a stockholder proposal to the extent such proposal is not submitted in accordance with the Restated Bylaws.
|
| • |
No stockholder actions by written consent: No stockholder or group of stockholders may take action by written consent. Along with the advance notice requirements described above, this provision also gives
our Board of Directors and management more time to react to proposed stockholder actions.
|
| • |
Super majority requirement for stockholder amendments to the Restated Bylaws: Stockholder proposals to alter or amend our Restated Bylaws or to adopt new bylaws can only be approved by the affirmative
vote of at least 66 2/3% of the outstanding shares of our common stock.
|
| • |
No ability of stockholders to call a special meeting of the stockholders: A special meeting of the stockholders, other than as required by statute, may be called at any time by the Board of Directors, the
chairman of the Board of Directors, or the president, and any power of stockholders to call a special meeting of stockholders is specifically denied. Accordingly, stockholders, even those who represent a significant percentage of our
shares of common stock, may need to wait for the annual meeting before nominating directors or raising other business proposals to be voted on by the stockholders.
|
| • |
Annual variations, actual or anticipated, in our operating results;
|
| • |
Significant changes in our management;
|
| • |
Large purchases or sales of common stock or derivative transactions related to our stock;
|
| • |
Actual or anticipated announcements of new products or services by us or competitors;
|
| • |
General conditions in the markets in which we compete; and
|
| • |
General social, political, economic, and financial conditions, including significant volatility in the global financial markets.
|
| Item 1B. |
Unresolved Staff Comments
|
| Item 2. |
Properties
|
| Item 3. |
Legal Proceedings
|
|
Item 5.
|
Market for the Registrant’s Common Equity, Related Stockholder Matters and Issuer Purchases of Equity Securities
|
|
Item 7.
|
Management’s Discussion and Analysis of Financial Condition and Results of Operations (Dollar
amounts in this section are in thousand)
|
|
2024
|
2023
|
|||||||
|
Revenue
|
$
|
5
|
$
|
7
|
||||
|
2024
|
2023
|
|||||||
|
Research and Development
|
$
|
6,038
|
$
|
9,713
|
||||
|
2024
|
2023
|
|||||||
|
Selling, General and Administrative
|
$
|
14,364
|
$
|
21,739
|
||||
|
2024
|
2023
|
|||||||
|
Interest and Other Income
|
$
|
2,225
|
$
|
3,495
|
||||
|
2024
|
2023
|
|||||||
|
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
||||
|
State taxes, net of federal benefit
|
(0.01
|
)%
|
(0.01
|
)%
|
||||
|
Valuation allowance
|
(20.50
|
)%
|
(20.31
|
)%
|
||||
|
Stock based compensation
|
(0.62
|
)%
|
(0.58
|
)%
|
||||
|
R&D Credit
|
1.55
|
%
|
2.20
|
%
|
||||
|
Other
|
(1.41
|
)%
|
(2.02
|
)%
|
||||
|
Effective income tax rate
|
0.01
|
%
|
0.28
|
%
|
||||
| Item 7A. |
Quantitative and Qualitative Disclosures about Market Risk
|
|
Page
|
|
|
29
|
|
|
31
|
|
|
32
|
|
|
33
|
|
|
34
|
|
|
35
|
|
|
36
|
|
Description of the Matter
|
Other Investments
As discussed in Note 2 to the financial statements, in 2023 the Company purchased equity interests in two private entities. Given that
the entities do not have a readily determinable fair market value, the investments in the entities are measured at cost minus impairment, plus or minus adjustments resulting from observable price changes in orderly transactions for
the identical or a similar investment of the same issuer minus impairment, if any in accordance with Financial Accounting Standards Board Accounting Standards Codification Topic 321: Investments - Equity Securities. Management must
consider various factors, including the Company’s ability to apply significant influence to the overall operations of the entities and also evaluate the investments as of each reporting period to determine if there are any factors
that would impact the recorded value of Other Investments reflected on the consolidated balance sheet.
Our determination that the classification and the valuation of Other Investments is a critical audit matter results from the significant
judgment by management when assessing the recognition method, the limited availability of public information related to the entities, and the subjectivity of the qualitative factors involved in the assessment. This in turn led to a
high degree of auditor judgment, subjectivity, and effort in performing procedures relating to management’s assessment of the recognition method and valuation of Other Investments.
|
|
Audit Procedures
|
Our principal audit procedures related to the Company’s Other Investments included the following:
- We evaluated
management’s analysis regarding their ability to apply significant influence in the operations of the entities by obtaining information of the ownership percentage of the entities, composition of the respective boards, and any other
relevant factors in determining their recognition method being recognized as cost in accordance with Accounting Standards Codification 321.
- We also evaluated
management’s assessment of impairment factors or any observable transactions of the entities through the year to determine whether an adjustment in the recognized value was necessary. This includes testing management’s internal
analysis as well as reviewing for any publicly available data regarding any factors or events that could impact the entities’ values.
|
|
As of
December 31, 2024
|
As of
December 31, 2023
|
|||||||
|
ASSETS
|
||||||||
|
Current assets:
|
||||||||
|
Cash and cash equivalents
|
$
|
23,296
|
$
|
26,289
|
||||
|
Investments available for sale
|
14,786
|
27,258
|
||||||
|
Accounts receivables
|
—
|
2
|
||||||
|
Prepaid expenses and other current assets
|
122
|
282
|
||||||
|
Total current assets
|
38,204
|
53,831
|
||||||
|
Prepaid expenses and other assets
|
8,838
|
4,014
|
||||||
|
Property and equipment, net
|
67
|
67
|
||||||
|
Other investments
|
2,500
|
2,500
|
||||||
|
Total assets
|
$
|
49,609
|
$
|
60,412
|
||||
|
LIABILITIES AND STOCKHOLDERS’ EQUITY
|
||||||||
|
Current liabilities:
|
||||||||
|
Accounts payable and accrued liabilities
|
$
|
336
|
$
|
440
|
||||
|
Accrued payroll and related expenses
|
257
|
316
|
||||||
|
Other liabilities, current
|
6,602
|
498
|
||||||
|
Total current liabilities
|
7,195
|
1,254
|
||||||
|
|
||||||||
|
Other liabilities
|
2,791
|
3,145
|
||||||
|
Total liabilities
|
9,986
|
4,399
|
||||||
|
Commitments and contingencies (Note 4)
|
||||||||
|
|
||||||||
|
Stockholders’ equity:
|
||||||||
|
Preferred stock, par value $0.0001 per share Authorized: 10,000,000 shares at December 31, 2024
and December 31, 2023, Issued and outstanding: 0 shares at December 31, 2024 and December 31, 2023
|
—
|
—
|
||||||
|
Common stock, par value $0.0001 per share
|
||||||||
|
Authorized: 100,000,000 shares at December 31, 2024 and December 31, 2023, Issued and outstanding: 4,238,581
and 3,618,431 shares, at December 31, 2024 and December 31, 2023, respectively
|
— |
— | ||||||
|
Additional paid-in capital
|
244,293
|
242,520
|
||||||
|
Accumulated deficit
|
(204,670
|
)
|
(186,495
|
)
|
||||
|
Accumulated other comprehensive loss
|
— |
|
(12
|
)
|
||||
|
Total stockholders’ equity
|
39,623
|
56,013
|
||||||
|
Total liabilities and stockholders’ equity
|
$
|
49,609
|
$
|
60,412
|
||||
|
|
Year Ended
December 31, 2024
|
Year Ended
December 31, 2023
|
||||||
|
Revenue
|
$
|
5
|
$
|
7
|
||||
|
Operating expense:
|
||||||||
|
Research and development
|
6,038
|
9,713
|
||||||
|
Selling, general and administrative expenses
|
14,364
|
21,739
|
||||||
|
Total operating expense
|
20,402
|
31,452
|
||||||
|
(Loss) from operations
|
(20,397
|
)
|
(31,445
|
)
|
||||
|
Interest and other income, net
|
2,225
|
3,495
|
||||||
|
(Loss) before taxes
|
(18,172
|
)
|
(27,950
|
)
|
||||
|
Income tax (provision) benefit
|
(3
|
)
|
79
|
|||||
|
Net (loss)
|
$
|
(18,175
|
)
|
$
|
(27,871
|
)
|
||
|
Basic (loss) per share
|
$
|
(5.05
|
)
|
$
|
(7.79
|
)
|
||
|
Diluted (loss) per share
|
$
|
(5.05
|
)
|
$
|
(7.79
|
)
|
||
|
Weighted average shares outstanding basic
|
3,596
|
3,579
|
||||||
|
Weighted average shares outstanding diluted
|
3,596
|
3,579
|
||||||
|
|
Year Ended
December 31, 2024
|
Year Ended
December 31, 2023
|
||||||
|
Net (loss)
|
$
|
(18,175
|
)
|
$
|
(27,871
|
)
|
||
|
Other comprehensive (loss) income, net of tax:
|
||||||||
|
Change in unrealized gain on investments, net
|
15
|
306
|
||||||
|
Change in foreign currency translation, net
|
(3
|
)
|
(4
|
)
|
||||
|
Total other comprehensive gain, net of tax
|
12
|
302
|
||||||
|
Comprehensive (loss)
|
$
|
(18,163
|
)
|
$
|
(27,569
|
)
|
||
| Year Ended |
||||||||
| December 31, |
||||||||
|
2024
|
2023
|
|||||||
|
Total shareholders’ equity, beginning balances
|
$
|
56,013
|
$
|
152,244
|
||||
|
Common stock and additional paid-in capital:
|
||||||||
|
Beginning balances
|
242,520
|
239,753
|
||||||
|
Common stock issued for options/RSUs/RS, net
|
(129
|
)
|
(11
|
)
|
||||
|
Stock-based compensation
|
1,902
|
2,778
|
||||||
|
Ending balances
|
244,293
|
242,520
|
||||||
|
Accumulated deficit
|
||||||||
|
Beginning balances
|
(186,495
|
)
|
(87,195
|
)
|
||||
|
Net (loss)
|
(18,175
|
)
|
(27,871
|
)
|
||||
|
Dividends
|
—
|
(71,429
|
)
|
|||||
|
Ending balances
|
(204,670
|
)
|
(186,495
|
)
|
||||
|
Accumulated other comprehensive loss:
|
||||||||
|
Beginning balances
|
(12
|
)
|
(314
|
)
|
||||
|
Change in unrealized investment (loss) gain, net
|
15
|
306
|
||||||
|
Change in foreign currency translation, net
|
(3
|
)
|
(4
|
)
|
||||
|
Ending balances
|
—
|
(12
|
)
|
|||||
|
Total shareholders’ equity, ending balances
|
$
|
39,623
|
$
|
56,013
|
||||
|
Dividends per share
|
$ | — | $ | 20 | ||||
|
|
Year Ended
December 31, 2024
|
Year Ended
December 31, 2023
|
||||||
|
Cash flows from operating activities:
|
||||||||
|
Net (loss)
|
$
|
(18,175
|
)
|
$
|
(27,871
|
)
|
||
|
Adjustments to reconcile net (loss) to net cash from operating activities:
|
||||||||
|
Depreciation
|
21
|
9
|
||||||
|
Stock-based compensation
|
1,902
|
2,778
|
||||||
|
Bad debt
|
1 | 15 | ||||||
|
Changes in assets and liabilities:
|
||||||||
|
Prepaid expenses and other current assets
|
848
|
(3,369
|
)
|
|||||
|
Accounts payable and accrued liabilities
|
(104
|
)
|
67
|
|||||
|
Other liabilities
|
238
|
3,596
|
||||||
|
Accrued payroll and related expenses
|
(59
|
)
|
5
|
|||||
|
Accounts receivable
|
1
|
(3
|
)
|
|||||
|
Net cash used in operating activities
|
(15,327
|
)
|
(24,773
|
)
|
||||
|
Cash flows from investing activities:
|
||||||||
|
Purchase of property and equipment
|
(22
|
)
|
(65
|
)
|
||||
|
Purchase of investments at cost
|
— | (2,500 | ) | |||||
|
Purchase of investments
|
(28,625
|
)
|
(47,215
|
)
|
||||
|
Proceeds from sale or maturity of investments
|
41,110
|
85,721
|
||||||
|
Net cash provided by investing activities
|
12,463
|
35,941
|
||||||
|
Cash flows from financing activities:
|
||||||||
|
Dividend
|
— | (71,429 | ) | |||||
|
Withholding taxes paid on cashless exercise of restricted stock and restricted stock units
|
(129
|
)
|
(11
|
)
|
||||
|
Net cash used in financing activities
|
(129
|
)
|
(71,440
|
)
|
||||
|
Net (decrease) in cash and cash equivalents
|
(2,993
|
)
|
(60,272
|
)
|
||||
|
Cash and cash equivalents, beginning of period
|
26,289
|
86,561
|
||||||
|
Cash and cash equivalents, end of period
|
$
|
23,296
|
$
|
26,289
|
||||
|
Cash paid for income taxes
|
$
|
3
|
|
—
|
||||
| Non-cash transaction |
||||||||
|
ROU asset and lease liability
|
$ | 5,512 | $ | 3,689 | ||||
|
December 31
|
||||||||
|
2024
|
2023
|
|||||||
|
Office furniture
|
$
|
165
|
$
|
143
|
||||
|
Computer equipment
|
92
|
92
|
||||||
|
Total
|
257
|
235
|
||||||
|
Less accumulated depreciation
|
(190
|
)
|
(168
|
)
|
||||
|
Total property and equipment, net
|
$
|
67
|
$
|
67
|
||||
|
Options Outstanding
|
Options Vested and Exercisable
|
|||||||||||||||||||||||
|
Range of
Exercise Prices |
Number
Outstanding
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
Number
Exercisable
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Weighted
Average
Exercise
Price
|
||||||||||||||||||
| $ 10.00 - 29.80 | 35,438 | 7.45 | $ |
28.47 | 24,219 | 7.47 | $ |
27.85 | ||||||||||||||||
|
$ 47.00
- 138.40
|
222,254
|
3.81
|
$
|
90.17
|
216,883
|
3.74
|
$
|
90.32
|
||||||||||||||||
|
257,692
|
4.31
|
$
|
81.69
|
241,102
|
4.12
|
$
|
84.04
|
|||||||||||||||||
|
Options
|
||||||||||||||||
|
Number
|
Weighted
Average
Exercise
Price
|
Weighted
Average
Remaining
Contractual
Life (Years)
|
Aggregate
Intrinsic
Value
|
|||||||||||||
|
Outstanding, December 31, 2022
|
340,798
|
$
|
106.60
|
—
|
$
|
—
|
||||||||||
|
Options granted
|
1,875
|
10.00
|
—
|
—
|
||||||||||||
|
Options exercised
|
—
|
—
|
—
|
—
|
||||||||||||
|
Options cancelled
|
(12,656
|
)
|
510.21
|
—
|
—
|
|||||||||||
|
Outstanding, December 31, 2023
|
330,017
|
$
|
90.63
|
—
|
$
|
—
|
||||||||||
|
Options granted
|
—
|
—
|
—
|
—
|
||||||||||||
|
Options exercised
|
—
|
—
|
—
|
—
|
||||||||||||
|
Options cancelled
|
(72,325
|
)
|
123.61
|
—
|
—
|
|||||||||||
|
Outstanding, December 31, 2024
|
257,692
|
$
|
81.69
|
4.31
|
$
|
—
|
||||||||||
|
Options exercisable, December 31, 2024
|
241,102
|
$
|
84.04
|
4.12
|
$
|
—
|
||||||||||
|
RSUs
|
||||||||||||
|
Number
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
||||||||||
|
Outstanding, December 31, 2022
|
27,605
|
$
|
73.00
|
$
|
—
|
|||||||
|
RSUs granted
|
1,250
|
10.00
|
—
|
|||||||||
|
RSUs vested
|
(11,405
|
)
|
83.81
|
—
|
||||||||
|
RSUs cancelled
|
—
|
—
|
—
|
|||||||||
|
Outstanding, December 31, 2023
|
17,450
|
$
|
60.81
|
$
|
—
|
|||||||
|
RSUs granted
|
—
|
—
|
—
|
|||||||||
|
RSUs vested
|
(7,971
|
)
|
70.88
|
—
|
||||||||
| RSUs cancelled |
(3,376 | ) | 58.91 | — | ||||||||
|
Outstanding, December 31, 2024
|
6,103
|
$
|
49.20
|
$
|
—
|
|||||||
|
Restricted Stock
|
||||||||||||
|
|
Number
|
Weighted
Average
Grant Date
Fair Value
|
Aggregate
Intrinsic
Value
|
|||||||||
|
Outstanding, December 31, 2022
|
—
|
$
|
—
|
$
|
—
|
|||||||
|
Restricted stock granted
|
36,927
|
9.12
|
—
|
|||||||||
|
Restricted stock vested
|
(3,617
|
)
|
9.19
|
—
|
||||||||
|
Restricted stock cancelled
|
(604
|
)
|
9.60
|
—
|
||||||||
|
Outstanding, December 31, 2023
|
32,706
|
$
|
9.11
|
$
|
—
|
|||||||
| Restricted stock granted |
649,000 | 5.91 | — | |||||||||
| Restricted stock vested |
(12,866 | ) | 9.35 | — | ||||||||
| Restricted stock cancelled |
(36,025 | ) | 7.97 | — | ||||||||
| Outstanding, December 31, 2024 | 632,815 | $ |
5.95 | $ |
1,215 | |||||||
|
Stock-Based Compensation by Type of Award
|
Year Ended
December 31, 2024
|
Year Ended
December 31, 2023
|
||||||
|
Stock options
|
$
|
1,240
|
$
|
1,960
|
||||
|
RSUs
|
333
|
778
|
||||||
| Restricted stock |
329 | 40 | ||||||
|
Total stock-based compensation expense
|
$
|
1,902
|
$
|
2,778
|
||||
|
Year Ended
December 31, 2024
|
Year Ended
December 31, 2023
|
|||||||
|
Expected stock price volatility
|
—
|
%
|
81.39
|
%
|
||||
|
Risk-free interest rate
|
—
|
%
|
3.9
|
%
|
||||
| Expected life term |
— | 5.5 years |
||||||
|
Expected dividends
|
—
|
%
|
0
|
% |
||||
| Year Ended December 31, | ||||||||
|
2024
|
2023
|
|||||||
|
Net (loss)
|
$
|
(18,175
|
)
|
$
|
(27,871
|
)
|
||
|
Basic weighted average number of shares outstanding
|
3,596 | 3,579 | ||||||
|
Effect of dilutive securities
|
—
|
—
|
||||||
|
Diluted weighted average number of shares outstanding
|
3,596
|
3,579
|
||||||
|
Basic (loss) per share
|
$
|
(5.05
|
)
|
$
|
(7.79
|
)
|
||
|
Diluted (loss) per share
|
$
|
(5.05
|
)
|
$
|
(7.79
|
)
|
||
|
Warrants
Issued
|
Exercise
Price
|
Outstanding and
Exercisable
December 31, 2024
|
Issued
|
Exercised
|
Terminated /
Cancelled
|
Outstanding and
Exercisable
December 31, 2023
|
Expiration Date
|
|||||||||||||||||||||
|
1,250
|
$
|
115
|
1,250
|
—
|
—
|
—
|
1,250
|
April 30, 2025
|
||||||||||||||||||||
|
Year Ended
December 31, 2024 |
Year Ended
December 31, 2023 |
|||||||
|
Current:
|
||||||||
|
Federal
|
$
|
—
|
$
|
—
|
||||
|
State
|
3
|
2
|
||||||
|
Foreign
|
— | — | ||||||
|
|
3
|
2
|
||||||
|
Deferred:
|
||||||||
|
Federal
|
—
|
(79
|
)
|
|||||
|
State
|
—
|
(2
|
)
|
|||||
|
|
— | (81 | ) | |||||
|
Total income tax (benefit) provision
|
$ | 3 |
$
|
(79
|
)
|
|||
|
Year Ended
December 31, 2024 |
Year Ended
December 31, 2023 |
|||||||
|
United States federal statutory rate
|
21.00
|
%
|
21.00
|
%
|
||||
|
State taxes, net of federal benefit
|
(0.01
|
)%
|
(0.01
|
)%
|
||||
|
Valuation allowance
|
(20.50
|
)%
|
(20.31
|
)%
|
||||
|
Stock based compensation
|
(0.62
|
)%
|
(0.58
|
)%
|
||||
|
R&D Credit
|
1.55
|
%
|
2.20
|
%
|
||||
|
Other
|
(1.41
|
)%
|
(2.02
|
)%
|
||||
|
Effective income tax rate
|
0.01 | % |
0.28
|
%
|
||||
|
As of
December 31, 2024 |
As of
December 31, 2023 |
|||||||
|
Deferred tax assets:
|
||||||||
|
Reserves and accruals
|
$
|
2,066
|
$
|
65
|
||||
|
Research and development credits and other credits
|
1,115
|
1,110
|
||||||
|
Net operating loss carry forward
|
17,907
|
15,262
|
||||||
|
Stock based compensation
|
3,451
|
4,360
|
||||||
|
Other
|
2,796
|
2,382
|
||||||
|
Total deferred tax assets
|
$
|
27,335
|
$
|
23,179
|
||||
|
Valuation allowance
|
(25,460
|
)
|
(23,179
|
)
|
||||
|
Deferred tax assets after valuation allowance
|
$
|
1,875
|
—
|
|||||
|
Total deferred tax liability
|
||||||||
| ROU |
$ | (1,870 | ) | — | ||||
| Depreciation and amortization |
(5 | ) | — | |||||
|
Net deferred tax assets
|
$
|
—
|
$
|
—
|
||||
|
December 31, 2024
|
||||||||||||||||||||||||
|
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
|
Cash
|
$
|
1,777
|
$
|
—
|
$
|
—
|
$
|
1,777
|
$
|
1,777
|
$
|
—
|
||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
20,077
|
—
|
—
|
20,077
|
20,077
|
—
|
||||||||||||||||||
|
U.S. agency and treasury securities
|
16,204
|
25
|
(1
|
)
|
16,228
|
1,442
|
14,786
|
|||||||||||||||||
|
36,281
|
25
|
(1
|
)
|
36,305
|
21,519
|
14,786
|
||||||||||||||||||
|
Total
|
$
|
38,058
|
$
|
25
|
$
|
(1
|
)
|
$
|
38,082
|
$
|
23,296
|
$
|
14,786
|
|||||||||||
|
December 31, 2023
|
||||||||||||||||||||||||
|
Adjusted
Cost |
Unrealized
Gains |
Unrealized
Losses |
Fair
Value |
Cash
and Cash Equivalents |
Investments
Available for Sale |
|||||||||||||||||||
|
Cash
|
$
|
1,452
|
$
|
—
|
$
|
—
|
$
|
1,452
|
$
|
1,452
|
$
|
—
|
||||||||||||
|
Level 1:
|
||||||||||||||||||||||||
|
Mutual funds
|
20,040
|
—
|
—
|
20,040
|
20,040
|
—
|
||||||||||||||||||
|
U.S. agency and treasury securities
|
32,046 | 27 | (18 | ) | 32,055 | 4,797 | 27,258 | |||||||||||||||||
|
52,086
|
27
|
(18
|
)
|
52,095
|
24,837
|
27,258
|
||||||||||||||||||
|
Total
|
$
|
53,538
|
$
|
27
|
$
|
(18
|
)
|
$
|
53,547
|
$
|
26,289
|
$
|
27,258
|
|||||||||||
|
Due in 2025
|
$
|
6,946
|
||
|
Due in 2026
|
$
|
927
|
||
|
Due in 2027
|
$
|
954
|
||
|
Due in 2028
|
$
|
983
|
||
|
Thereafter
|
$
|
336
|
||
|
Total undiscounted lease liability
|
$
|
10,146
|
||
| Less: imputed interest |
$ | (757 | ) | |
| Total lease liability |
$ | 9,389 |
| Item 9. |
Changes in and Disagreements with Accountants on Accounting and Financial Disclosure
|
| Item 9A. |
Controls and Procedures
|
| Item 9B. |
Other Information
|
| Item 9C. |
Disclosure Regarding Foreign Jurisdictions that Prevent Inspections
|
| Item 10. |
Directors, Executive Officers and Corporate Governance
|
| Item 11. |
Executive Compensation
|
| Item 12. |
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters
|
|
Plan Category
|
Number of
Securities to be
Issued Upon
Exercise of
Outstanding
Options and
RSUs
|
Weighted-Average
Exercise Price of
Outstanding
Options and RSUs
|
Number of
Securities
Remaining
Available for
Future Issuance
Under Equity
Compensation
Plans
|
||||||
|
Equity compensation plans approved by security holders
|
263,790 |
$80.94
|
575,055
|
||||||
|
Equity compensation plans not approved by security holders
|
—
|
—
|
|||||||
|
Total
|
263,790
|
$80.94
|
575,055
|
| Item 13. |
Certain Relationships and Related Transactions, and Director Independence
|
| Item 14. |
Principal Accounting Fees and Services
|
| Item 15. |
Exhibits and Financial Statement Schedules
|
|
|
(a) |
The following documents are filed as part of this Annual Report on Form 10-K
|
|
|
(1) |
Financial Statements: See the Index to Consolidated Financial Statements under Item 8 of this Annual Report on Form 10-K.
|
|
|
(2) |
Financial Statement Schedule: Financial statement schedules are omitted because they are not applicable, or the required information is shown in the financial
statements or notes thereto. All other schedules are omitted because of the absence of conditions under which they are required or because the required information is given in the financial statements or the notes thereto.
|
|
|
(3) |
Exhibits: The documents listed in the Exhibit Index of this Annual Report on Form 10-K are incorporated by reference or are filed with this Annual Report on Form
10-K, in each case as indicated therein (numbered in accordance with Item 601 of Regulation S-K).
|
|
Exhibit
Number
|
Description
|
Incorporated by reference herein
|
|||||
|
Form
|
Exhibit
No.
|
Filing Date
|
File No.
|
Filed
Herewith
|
|||
|
3.1
|
8-K
|
3.1
|
11/01/2007
|
000-26895
|
|||
|
3.2
|
8-K
|
3.1
|
10/25/2023
|
001-33852
|
|||
|
3.3
|
8-K
|
3.1
|
1/27/2023
|
001-33852
|
|||
|
4.1
|
S-3
|
4.1
|
07/30/2018
|
333-226413
|
|||
|
4.2
|
S-3
|
4.2
|
07/30/2018
|
333-226413
|
|||
|
4.3
|
S-3
|
4.4
|
07/30/2018
|
333-226413
|
|||
|
4.4
|
|
|
|
|
X | ||
|
10.1
|
10-K
|
10.1
|
03/18/2019
|
001-33852
|
|||
|
10.2*
|
10-Q
|
10.2
|
05/10/2012
|
001-33852
|
|||
|
10.3*
|
10-Q
|
4.5
|
05/10/2011
|
001-33852
|
|||
|
10.4*
|
10-Q
|
10.3
|
05/10/2012
|
001-33852
|
|||
|
10.5*
|
DEF 14A
|
Appendix A
|
04/13/2021
|
001-33852
|
|||
|
10.6*
|
8-K
|
10.1
|
06/18/2024
|
001-33852
|
|||
|
10.7*
|
10-K
|
10.6
|
03/02/2015
|
001-33852
|
|||
|
10.8*
|
10-K
|
10.7
|
03/02/2015
|
001-33852
|
|||
|
10.9*
|
10-Q
|
10.2
|
08/11/2023
|
001-33852
|
|||
|
10.10
|
8-K
|
10.4
|
07/12/2007
|
000-26895
|
|||
|
10.11**
|
8-K
|
10.6
|
07/12/2007
|
000-26895
|
|||
|
10.12
|
8-K
|
10.1
|
03/18/2008
|
001-33852
|
|||
|
10.13
|
8-K
|
10.5
|
07/12/2007
|
000-26895
|
|||
|
10.14
|
8-K
|
10.7
|
07/12/2007
|
000-26895
|
|||
|
10.15
|
8-K
|
10.8
|
07/12/2007
|
000-26895
|
|||
|
10.16**
|
10-Q/A
|
10.1
|
01/31/2011
|
001-33852
|
|||
|
10.17**
|
10-K
|
10.23
|
03/02/2015
|
001-33852
|
|||
|
10.18*
|
10-Q
|
10.1
|
11/08/2021
|
001-33852
|
|||
|
10.19*
|
10-K/A | 10.19 | 04/18/2024 | 001-33852 |
|
|
10.20
|
10-Q
|
10.2
|
05/15/2023
|
001-33852
|
|||
|
10.21*
|
10-K/A |
10.22 |
04/18/2024 |
001-33852 |
|
||
| 19.1 |
Insider Trading and Disclosure Compliance Proagram, as adopted
on March 30, 2023. |
X | |||||
|
21.1
|
10-K
|
21.1
|
03/16/2024
|
001-33852
|
|||
|
23.1
|
X
|
||||||
|
24.1
|
X
|
||||||
|
31.1
|
X
|
||||||
|
31.2
|
X
|
||||||
|
32.1†
|
X
|
||||||
|
32.2†
|
X
|
||||||
|
97.1*
|
10-K/A |
97.1 |
04/18/2024 | 001-33852 |
|
||
|
101.INS
|
XBRL Instance Document
|
X
|
|||||
|
101.SCH
|
XBRL Taxonomy Extension Schema Document
|
X
|
|||||
|
101.CAL
|
XBRL Taxonomy Extension Calculation Linkbase Document
|
X
|
|||||
|
101.DEF
|
XBRL Taxonomy Extension Definition Linkbase Document
|
X
|
|||||
|
101.LAB
|
XBRL Taxonomy Extension Label Linkbase Document
|
X
|
|||||
|
101.PRE
|
XBRL Taxonomy Extension Presentation Linkbase Document
|
||||||
|
104
|
Cover Page Interactive Data File (formatted as inline XBRL and contained in Exhibit 101)
|
X
|
| * |
Indicates management contract or compensatory plan.
|
| ** |
Confidential treatment has been granted by the SEC as to certain portions of this exhibit.
|
| *** |
Portions of this exhibit have been omitted pending a determination by the SEC as to whether these portions should be granted confidential treatment.
|
| † |
The certifications attached as Exhibit 32.1 and 32.2 that accompany this Report are not deemed filed with the Securities and Exchange Commission and are not to be incorporated by reference into any
filing of VirnetX Holding Corporation under the Securities Act or the Exchange Act, whether before or after the date of this Report, irrespective of any general incorporation language contained in such filing.
|
|
VirnetX Holding Corporation
|
||
|
By:
|
/s/ Kendall Larsen
|
|
|
Name: Kendall Larsen
|
||
|
Title: Chief Executive Officer and President
|
||
|
Dated: March 17, 2025
|
||
|
Name
|
Capacity
|
Date
|
||
|
/s/Kendall Larsen
|
Director, Chief Executive Officer and President
|
March 17, 2025
|
||
|
Kendall Larsen
|
(Principal Executive Officer)
|
|||
|
/s/Katherine Allanson
|
Chief Financial Officer
|
March 17, 2025
|
||
|
Katherine Allanson
|
(Principal Financial Officer and
Principal Accounting Officer)
|
|||
|
/s/Heidy Chow
|
Director
|
March 17, 2025
|
||
|
Heidy Chow
|
||||
|
/s/Gary Feiner
|
Director
|
March 17, 2025
|
||
|
Gary Feiner
|
||||
|
/s/Michael F. Angelo
|
Director
|
March 17, 2025
|
||
|
Michael F. Angelo
|
||||
|
/s/Thomas M. O’Brien
|
Director
|
March 17, 2025
|
||
|
Thomas M. O’Brien
|
|
|
• |
Undesignated Preferred Stock. The ability to authorize undesignated
preferred stock makes it possible for our board of directors to issue one or more series of preferred stock with voting or other rights or preferences that could impede the success of any attempt to change control of our company. These
and other provisions may have the effect of deferring hostile takeovers or delaying changes in control or management of our company.
|
|
|
• |
Stockholder Meetings. Our Bylaws provide that a special meeting of
stockholders may be called only by resolution adopted by the board of directors.
|
|
|
• |
Requirements for Advance Notification of Stockholder Nominations and
Proposals. Our Bylaws establish advance notice procedures with respect to stockholder proposals and the nomination of candidates for election as directors, other than nominations made by or at the direction of the board of
directors or a committee of the board of directors.
|
|
|
• |
Board Classification. Our board of directors is divided into three
classes. The directors in each class will serve for a three-year term, one class being elected each year by our stockholders. This system of electing and removing directors may tend to discourage a third party from making a tender offer
or otherwise attempting to obtain control of us, because it generally makes it more difficult for stockholders to replace a majority of the directors.
|
|
|
• |
Stockholder Meetings; Limits on Ability of Stockholders to Act by Written
Consent. We have provided in our Certificate of Incorporation that our stockholders may not act by written consent. This limit on the ability of our stockholders to act by written consent may lengthen the amount of time
required to take stockholder actions. As a result, a holder controlling a majority of our capital stock would not be able to amend our Bylaws or remove directors without holding a meeting of our stockholders called in accordance with
our Bylaws.
|
|
|
• |
Amendment of Bylaws. Any amendment of our Bylaws requires approval by
holders of at least two-thirds of our outstanding capital stock entitled to vote generally in the election of directors.
|
|
|
• |
prior to the date of the transaction, the board of directors of the corporation approved either the business combination or the transaction which resulted in
the stockholder becoming an interested stockholder;
|
|
|
• |
the stockholder owned at least 85% of the voting stock of the corporation outstanding at the time the transaction commenced, excluding for purposes of
determining the number of shares outstanding (a) shares owned by persons who are directors and also officers, and (b) shares owned by employee stock plans in which employee participants do not have the right to determine confidentially
whether shares held subject to the plan will be tendered in a tender or exchange offer; or
|
|
|
• |
on or subsequent to the date of the transaction, the business combination is approved by the board and authorized at an annual or special meeting of
stockholders, and not by written consent, by the affirmative vote of at least two-thirds of the outstanding voting stock that is not owned by the interested stockholder.
|
|
I.
|
Adoption of Insider Trading Policy.
|
|
II.
|
Designation of Certain Persons.
|
|
|
A. |
Section 16 Individuals Must Pre-Clear All Trades. The Board of Directors of the Company (the “Board”) has determined those persons who are “executive officers” and who are thus, along with the members of the Board
(collectively, the “Section 16 Individuals”), subject to the reporting and liability provisions of Section 16 of the Securities Exchange Act of 1934, as amended (the “1934 Act”) and the related rules and regulations. These Section 16 Individuals are subject to both the blackout periods and the pre-clearance procedures imposed by the Policy. Except
for pre-approved trading plans as discussed in “Exceptions to the General Policies” in the Policy, Section 16 Individuals must pre-clear all trades, even those occurring during an open trading window, in order to ensure compliance with
the Section 16 reporting requirements for such trades.
|
|
|
B. |
Everyone Else is Subject To Blackouts. The
Company has determined that all of its officers, directors, employees, and certain of its consultants are subject to the black-out periods imposed by the Policy. Under special circumstances, certain persons who are not Section 16
Individuals may come to have access to Inside Information for a period of time. During such period, such persons will also be subject to the pre-clearance procedures applicable to Section 16 Individuals. Individuals subject to quarterly
blackout periods will be informed by the Compliance Officer that they are listed on the covered persons list maintained by the Compliance Officer (the “Covered Persons List”).
|
|
|
III. |
Oversight of Policy. The Board, assisted by
the Compliance Officer, shall oversee the implementation and enforcement of the Policy.
|
|
|
IV. |
Appointment of Compliance Officer. The
Company has appointed Kendall Larsen (or his designee) as the Company’s Insider Trading Compliance Officer (the “Compliance Officer”). In order to ensure compliance with the
Policy and in particular Section V.E. of the Policy, the Compliance Officer is authorized to designate one or more persons to assist in administering the Policy.
|
|
|
V. |
Duties of Compliance Officer.
|
|
|
A. |
Pre-clearing all transactions involving the Company’s stock by the Section 16 Individuals, in order to determine compliance with the Policy, insider trading laws, Section 16 of
the 1934 Act, Rule 144 promulgated under the Securities Act of 1933, and other applicable securities laws, as adopted and amended from time to time.
|
|
|
B. |
Assisting in the preparation and filing of Section 16 reports (Forms 3, 4, and 5) for all Section 16 Individuals, and other applicable reports (whether filed by the Company or
the individual), including providing memoranda and other appropriate materials to its officers and directors regarding compliance with Section 16, its related rules, and other applicable disclosure rules.
|
|
|
C. |
Serving as the designated recipient at the Company of copies of reports filed with the SEC by Section 16 Individuals under Section 16 of the 1934 Act and other reports required
by applicable disclosure rules.
|
|
|
D. |
Providing upon hire and making available, reminders to all Section 16 Individuals and other individuals subject to disclosure rules regarding their obligations to report or to
assist the Company in complying with its reporting obligations.
|
|
|
E. |
Establishing procedures designed to ensure that the Company will be in a position to comply with any securities law disclosure rules, either currently in force or that may be
adopted in the future, that apply to the Company and relate to insider transactions involving Company stock. The procedures may include requiring an insider to notify the Compliance Officer sufficiently in advance of engaging in a
transaction both to allow pre-clearance of the transaction for purposes of the Policy and to prepare any reports the Company is required to file, and requiring an insider to make available to the Company all information necessary for the
Company to comply with applicable disclosure rules.
|
|
|
F. |
Performing periodic cross-checks of available materials, which may include Forms 3, 4, and 5, Form 144, officer and director questionnaires, and reports received from the
Company’s stock administrator and transfer agent, to determine trading activity by officers, directors, and others who have, or may have, access to Inside Information.
|
|
|
G. |
Making available the Policy (or a summary of the Policy) to all individuals subject to the Policy, and providing the Policy and other appropriate materials to new employees and
consultants, and otherwise ensuring that appropriate education of affected individuals is accomplished.
|
|
|
H. |
Providing periodic reports on ongoing compliance matters, including any disciplinary actions, regarding the Policy to the Board if requested, on a quarterly basis, and
otherwise assisting the Board in implementation of the Policy and this Compliance Program.
|
|
|
1. |
Don’t trade while in possession of material nonpublic information. From time to time you may come into possession of material nonpublic information as a result of your service or relationship with the Company. You may not buy, sell, trade or otherwise transact in any stock of the Company or other securities involving the Company’s stock at any time
while you possess material nonpublic information concerning the Company (whether during a “blackout period,” if applicable, or at any other time). It is not
an excuse that you did not “use” the information in your transaction. You must wait to trade until newly released material information has been public for at least two full
trading days. The term “trading day” means a day on which national stock exchanges are open for trading. A “full” trading day has elapsed when, after the public disclosure, trading in the relevant security has opened and then
closed.
|
|
|
2. |
Don’t trade during blackout periods. The
Company prohibits all officers, directors, employees, and certain other individuals designated by the Company from trading during black-out periods (whether regularly scheduled blackout periods, or special blackout periods implemented from time to time). It is your responsibility to know when the Company’s regularly
quarterly blackout periods begin and end. If you are informed that the Company has implemented a special blackout period, you may not disclose the fact that
trading has been suspended to anyone, including other Company employees (who may themselves not be subject to the blackout), family members (other than those subject to this Policy who would be prohibited from trading because you are),
friends, or brokers. You should treat the imposition of a special blackout period as material nonpublic information. Please see the “Blackout Period” under “Definitions used in this Policy” for more information regarding special blackout
periods.
|
|
|
3. |
Pre-clear trades involving Company stock. If
you are unsure about whether information you possess would qualify as material nonpublic information and whether you therefore should refrain from trading in the Company’s stock, you should pre-clear any transactions involving Company
stock that you intend to engage in with the Compliance Officer. If the Compliance Officer is seeking to pre-clear a transaction, he or she should pre-clear the transaction with the Chief Financial Officer and/or the chair of the Audit
Committee of the Board.
|
|
|
4. |
Don’t give nonpublic information to others.
Don’t give nonpublic information concerning the Company (commonly referred to as “tipping”) to any other person, including other directors, officers, employees, consultants, contractors or advisors whose roles do not require them to have
the information, and including friends, family members, business associates, investors or consulting firms, without prior written authorization from the Compliance Officer, and don’t make recommendations or express opinions about trading
in the Company’s stock under any circumstances, regardless of whether you derive any profit or personal benefit from doing so.
|
|
|
5. |
Don’t discuss Company information with the press, analysts, or other persons
outside of the Company. Announcements of Company information is regulated by Company policy (separate from this Policy) and may only be made by persons specifically authorized by the Company to make
such announcements. Laws and regulations govern the nature and timing of such announcements to outsiders or the public and unauthorized disclosure could result in substantial liability for you, the Company, and its management. If you
receive inquiries from any third party about Company information, you should notify the Compliance Officer immediately.
|
|
|
6. |
Don’t participate in Internet message boards, blogs, or social media platforms in
which the Company, its business, or its stock is discussed.
|
|
|
7. |
Reporting violations. If you believe someone
is violating this Policy or otherwise using material nonpublic information that they learned through their position at the Company to trade securities, you should report it to the Compliance Officer, or if the Compliance Officer is
implicated in your report, then you should report it to the Company’s Chief Financial Officer. If your situation requires that your identity be kept secret, your anonymity will be preserved to the greatest extent reasonably possible.
|
|
|
8. |
Don’t engage in speculative transactions involving the Company’s stock. Don’t engage in any transactions that suggest you are speculating in the Company’s stock (that is, that you are trying to profit in short-term movements, either increases or decreases, in the stock price).
|
|
|
9. |
Don’t engage in hedging or derivative transactions involving Company stock. You may not, directly or indirectly, engage in hedging or derivative transactions, including (a) trade in publicly-traded options, such as puts and calls, and other derivative securities with respect to the Company’s securities (other than stock options, restricted stock units and other
compensatory awards issued to you by the Company) or (b) purchase financial instruments (including prepaid variable forward contracts, equity swaps, collars and exchange funds), or otherwise engage in transactions, that hedge or offset,
or are designed to hedge or offset, any decrease in the market value of Company equity securities either (i) granted to you by the Company as part of your compensation or (ii) held, directly or indirectly, by you.
|
|
|
10. |
Pledging Transactions. You may not pledge
the Company's securities as collateral for any loan or as part of any other pledging transaction.
|
|
|
11. |
Margin Accounts. You may not hold the
Company's common stock in margin accounts.
|
|
|
12. |
Don’t engage in short sales involving Company stock. You may not engage in short sales (meaning the sale of a security that must be borrowed to make delivery) or “selling short against the box” meaning the sale of a security with a delayed delivery) with respect to Company securities.
Short sales may signal to the market possible bad news about the Company or a general lack of confidence in the Company’s prospects, and an expectation that the value of the Company’s securities will decline.
|
|
|
13. |
Observe the Section 16 liability rules applicable to officers, directors, and 10%
stockholders. Certain officers of the Company, directors, and 10% stockholders must also conduct their transactions in Company stock in a manner designed to comply with the “short-swing” trading rules
of Section 16(b) of the 1934 Act. The practical effect of these provisions is that officers and directors who purchase and sell, or sell and purchase, Company securities within a six-month period must disgorge all profits to the Company
whether or not they had any nonpublic information at the time of the transactions. Certain exemptions to the “short-swing” trading rules may apply, such as the exercise of stock options granted by an independent compensation committee. However, due to the complexity of these provisions and the potential for Section 16 liability, please direct any questions you have regarding such transactions to the Compliance
Officer before engaging in any transactions involving Company stock.
|
|
|
14. |
Comply with public securities law reporting requirements. Federal securities laws require that officers, directors, large stockholders, and affiliates of the Company publicly report transactions in Company stock (on Forms 3, 4, and 5 under Section 16, Form 144 with
respect to restricted and control securities, and, in certain cases, Schedules 13D and 13G). The Company takes these reporting requirements very seriously and requires that all persons subject to public reporting of Company stock
transactions adhere to the rules applicable to these forms. Where issues arise as to whether reporting is technically required (particularly issues that turn on facts specific to the transaction and the individuals involved, or on
unsettled issues of law), the Company encourages its insiders to choose to comply with the spirit and not the letter of the law — in other words, to err on the side of fully and promptly reporting the transaction even if not technically
required to do so.
|
|
|
15. |
Make sure your family members do not violate this Policy. Please remember that this Policy does apply to members of your immediate family, persons with whom you share a household, your economic dependents and any other individuals or entities whose transactions in
securities you influence, direct or control. Therefore, you are responsible for making sure that such persons and entities do not engage in any transaction that would
violate this Policy, in addition to separately ensuring you do not as well.
|
|
|
1. |
Purchases Under Employee Stock Option and Stock Purchase Plans. The exercise (without a sale or any other associated market activity) of stock options under the Company’s stock option plans and the
purchase of shares under the Company’s employee stock purchase plan, if any, are exempt from this Policy, since the other party to the transaction is the Company itself and the price does not vary with the market but is fixed by the terms
of the option agreement or the plan.
|
|
|
2. |
Compensation Awards from the Company. The
receipt and vesting of stock options, restricted stock units, restricted stock or other equity compensation awards from the Company.
|
|
|
3. |
Transactions Related to Tax Withholding Requirements. Net share withholding with respect to equity awards, as applicable, is exempt from this Policy where shares are withheld by the Company in order to satisfy tax withholding requirements, either as required by
either the Board (or a committee thereof) or the award agreement governing such equity award, or as you elect, if permitted by the Company, so long as the election is irrevocable and made in writing at a time when a trading blackout is
not in place and you are not in possession of material nonpublic information.
|
|
|
4. |
10b5-1 Trading Plans. The Company may
permit its directors, officers and employees to adopt written 10b5-1 trading plans in order to mitigate the risk of trading on material nonpublic information. These plans allow for individuals to enter into a prearranged trading plan as
long as the plan is not established or modified during a blackout period or when the individual is otherwise in possession of material nonpublic information. To be approved by the Company and qualify for the exception to this Policy, any
10b5 1 trading plan adopted by a director, officer or employee must be submitted to the Compliance Officer for approval and comply with the requirements set forth in the Company’s policy entitled “Requirements for Trading Plans.” If the
Compliance Officer is the requester, then the Company’s Chief Financial Officer must approve the written 10b5-1 trading plan.
|
|
|
5. |
Stock Split or Stock Dividend. Changes in
the number of the Company’s securities you hold due to a stock split or a stock dividend that applies equally to all securities of a class or similar transactions are exempt from this Policy.
|
|
|
6. |
Transfers by Will or the Laws of Descent and Distribution, or Change in Form of
Ownership. The trading restrictions under this Policy do not apply to transfers by will or the laws of descent and distribution, provided that prior written notice is provided to the Compliance
Officer, distributions or transfers for tax planning or estate planning purposes that effect only a change in the form of beneficial interest and in which your beneficial ownership and pecuniary interest in the transferred Company
securities does not change.
|
|
|
7. |
Other Exceptions. Any other exception from
this Policy must be approved by the Compliance Officer, in consultation with the Board or an independent committee of the Board. Please be aware that even if a transaction falls within one of the exceptions described above, you will need
to separately assess whether the transaction complies with applicable law. If you have any questions, please consult with the Compliance Officer.
|
|
|
1. |
Material Information. It is not possible to
define all categories of “material” information, but information should be regarded as material if a reasonable investor would be substantially likely to consider it important in deciding whether to buy, hold or sell securities of the
Company or view as significantly altering the total mix of information available in the marketplace about the Company as an issuer of the securities. In general, any information that could reasonably be expected to affect the market price
of a security is likely to be material. Either positive or negative information may be material.
|
|
|
a. |
financial results, key metrics, financial condition, earnings pre-announcements, guidance, projections or forecasts, particularly if inconsistent with the Company’s guidance or
the expectations of the investment community;
|
|
|
b. |
restatements of financial results, or material impairments, write-offs or restructurings;
|
|
|
c. |
changes in independent auditors, or notification that the Company may no longer rely on an audit report;
|
|
|
d. |
business plans, budgets customer lists and customer target lists;
|
|
|
e. |
creation of significant financial obligations, or any significant default under or acceleration of any financial obligation;
|
|
|
f. |
impending bankruptcy or financial liquidity problems;
|
|
|
g. |
significant developments involving business relationships, including actual or pending execution, modification or termination of significant agreements or orders with
customers, suppliers, distributors, manufacturers or other business partners;
|
|
|
h. |
significant information relating to the operation of product or service, such as new products or services, major modifications or performance issues, defects or recalls,
significant pricing changes or other announcements of a significant nature;
|
|
|
i. |
significant developments in research and development or relating to intellectual property;
|
|
|
j. |
significant legal or regulatory developments, whether positive or negative, actual or threatened, including litigation or resolving litigation;
|
|
|
k. |
major events involving the Company’s securities, including calls of securities for redemption, adoption of stock repurchase programs, option repricings, stock splits, changes
in dividend policies, public or private securities offerings, modification to the rights of security holders or notice of delisting;
|
|
|
l. |
significant corporate events, such as a pending or proposed merger, joint venture or tender offer, a significant investment, the acquisition or disposition of a significant
business or asset or a change in control of the Company;
|
|
|
m. |
major personnel changes, such as changes in senior management or employee layoffs;
|
|
|
n. |
data breaches or other cybersecurity events;
|
|
|
o. |
updates regarding any prior material disclosure that has materially changed; and
|
|
|
p. |
the existence of a special blackout period.
|
|
|
2. |
Nonpublic Information. Nonpublic information
is that which is not generally known or made available to the public. Information about the Company is considered to be nonpublic even if it is known within the Company but is not yet broadly disclosed to the general public for a
sufficient period to be reflected in the price of the security. The Company generally discloses information to the public either via press release or in the regular quarterly and annual reports that the Company is required to file with
the SEC. At least two full trading days must pass after the dissemination of information before such information is considered public. However, depending upon the form of the announcement and the nature of the information, it is possible
that information may not be fully absorbed by the marketplace until a later time. Any questions as to whether information is nonpublic should be directed to the Compliance Officer.
|
|
|
3. |
Blackout Period. During the end of each
fiscal quarter and until public disclosure of the financial results for that quarter, persons subject to this Policy may possess material nonpublic information about the expected financial results for the quarter. Even if you don’t
actually possess any such information, any trades by you during that period may give the appearance that you are trading on inside information. Accordingly, the Company has designated a regularly scheduled quarterly “blackout period” on
trading beginning with the twenty-fifth day of the last month of each quarter and ending at the start of the third full trading day after disclosure of the quarter’s financial results.
|
|
|
4. |
Trading Window. The period outside a
blackout period is referred to as the “trading window.” Trading windows that occur between the regularly-scheduled quarterly blackout periods can be “closed” by the imposition of a special blackout period if there are developments
meriting a suspension of trading by Company personnel.
|
|
Date
|
|
|
Signature
|
|
|
Printed Name
|
|
Person proposing to trade:
|
||
|
Proposed trade (type and amount):
|
||
|
Manner of trade:
|
||
|
Proposed trade date:
|
||
|
Affiliate of the Company:
|
☐ Yes ☐ No
|
|
☐
|
No blackout period. The proposed
trade will not be made during a quarterly or special blackout period.
|
|
☐
|
No prohibition under Insider Trading Policy. The person confirmed that the proposed transaction is not prohibited under the Insider Trading Policy.
|
|
☐
|
Section 16 compliance.* The person
confirmed that the proposed trade will not give rise to any potential liability under Section 16 as a result of matched past (or intended future) transactions.
|
|
☐
|
Form 4 filing.* A Form 4 has been or
will be completed and will be timely filed with the SEC, if applicable.
|
|
☐
|
Rule 144 compliance (Response required only from affiliates of the Company).
|
|
☐
|
The “current public information” requirement has been met (i.e., all 10‑Ks, 10‑Qs and other relevant
reports during the last 12 months have been filed);
|
|
☐
|
The shares that the person proposes to trade are not restricted or, if restricted, the applicable holding period has been met;
|
|
☐
|
Volume limitations (greater of 1% of outstanding securities of the same class or the average weekly trading volume during the last four weeks) are not exceeded, and the
person is not part of an aggregated group;
|
|
☐
|
The manner of sale requirements will be met (a “brokers’ transaction” or directly with a market maker or a “riskless principal transaction”); and
|
|
☐
|
A Form 144, if applicable, has been completed and will be timely filed with the SEC.
|
|
☐
|
Rule 10b‑5 concerns. The person has
been reminded that trading is prohibited when in possession of any material nonpublic information regarding the Company that has not been adequately disclosed to the public. The individual has discussed with the Compliance Officer any
information known to the individual or the Compliance Officer that the individual believes may be material.
|
|
Date:
|
|||
|
(Signature of Compliance Officer)
|
|||
|
(Print name of Compliance Officer)
|
|||
|
I am not aware of material nonpublic information regarding the Company. I am not trading on the basis of any material nonpublic information. The transaction is in
accordance with the Insider Trading Policy and applicable law. I intend to comply with any applicable reporting and disclosure requirements on a timely basis. I understand that I must execute the trade by the end of the second trading day
after the date on which the trade is cleared by the Compliance Officer. I understand that by signing below, I am not obligated to execute the trade.
|
|||
|
(Signature of person proposing trade)
|
|||
| 1. |
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2024;
|
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;
|
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;
|
| 4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
| (a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
| (b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
| (c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
|
| (d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
| 5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
|
| (a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information; and
|
| (b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ Kendall Larsen
|
|
|
Kendall Larsen
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
Date: March 17, 2025
|
| 1. |
I have reviewed this Annual Report on Form 10-K of VirnetX Holding Corporation for the fiscal year ended December 31, 2024;
|
| 2. |
Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which
such statements were made, not misleading with respect to the period covered by this report;
|
| 3. |
Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows
of the registrant as of, and for, the periods presented in this report;
|
| 4. |
The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal
control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:
|
| (a) |
Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant,
including its consolidated subsidiaries, is made known to us by others within those entities, particularly during the period in which this report is being prepared;
|
| (b) |
Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the
reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;
|
| (c) |
Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end
of the period covered by this report based on such evaluation; and
|
| (d) |
Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in
the case of an annual report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and
|
| 5. |
The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the
registrant’s board of directors (or persons performing the equivalent functions):
|
| (a) |
All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record,
process, summarize and report financial information; and
|
| (b) |
Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.
|
|
/s/ Katherine Allanson
|
|
|
Katherine Allanson
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
|
Date: March 17, 2025
|
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Kendall Larsen
|
|
|
Kendall Larsen
|
|
|
President and Chief Executive Officer
|
|
|
(Principal Executive Officer)
|
|
|
Date: March 17, 2025
|
|
|
(1) |
The Report fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934; and
|
|
|
(2) |
The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
|
|
/s/ Katherine Allanson
|
|
|
Katherine Allanson
|
|
|
Chief Financial Officer
|
|
|
(Principal Financial Officer and Principal Accounting Officer)
|
|
|
Date: March 17, 2025
|